Abbott Norvir
Executive Summary
Ritonavir oral solution and capsules gain traditional approval May 26. The protease inhibitor has been marketed under an accelerated approval for HIV treatment received March 1, 1996. Abbott has stopped marketing the capsules because of manufacturing problems, but has filed an NDA for a soft-gel capsule ("The Pink Sheet" April 5, In Brief)
You may also be interested in...
Abbott Norvir Returns To Market Via Contract Manufacturer
Abbott's HIV protease inhibitor Norvir capsules will be available the week of July 5 as a soft gelatin reformulation outsourced to a contract manufacturer.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011